The impact of high FOXP1 expression on FFS in immunochemotherapy-treated patients was additional to the Follicular Lymphoma International Prognostic Index.
We revealed that low levels of <i>miR-150</i> and high levels of its target, FOXP1, are associated with shorter overall survival in FL and suggest that <i>miR-150</i> could serve as a good biomarker measurable in formalin-fixed paraffin-embedded tissue.